Treatments · Entity Annotation Prototype (beta)

13articles mentioning treatments

21treatment mentions

1distinct treatments extracted

0%of mentions human-reviewed

Active filtersEntity: neoadjuvant immunotherapy ×

neoadjuvant immunotherapy

This treatment is selected. Its supporting articles are shown below.

Neoadjuvant immunotherapy13

Articles mentioning neoadjuvant immunotherapy

13 articles · page 2 of 2

Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial

jitc · abstract · 2025-08-04 · 1 matching annotations

76.5%

Neoadjuvant immunotherapy pembrolizumab non-small cell lung cancer NSCLC NCT0319746

… the overall survival was 82.7% at 24 and 36 months.Conclusions Neoadjuvant immunotherapy with pembrolizumab appears safe and feasible and is associated …

Browse treatments

neoadjuvant immunotherapy

Articles mentioning neoadjuvant immunotherapy

Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial